Shots:

• The first patient has enrolled in a P-III (IMforte) trial to evaluate the efficacy, safety, and PK of Zepzelca + Tecentriq (PD-L1 inhibitor) vs SoC in patients with es-SCLC, following induction therapy with carboplatin, etoposide, and atezolizumab. The trial is being conducted in collaboration with F. Hoffmann-La Roche
• The primary objective is to determine the ability to improve outcomes for patients with ES-SCLC, compared with SoC as measured by PFS and OS
• Additionally, the trial will support the sNDA for Zepzelca + Tecentriq as a 1L maintenance treatment of ES-SCLC. Zepzelca is an alkylating drug that binds guanine residues within DNA

Ref: PR Newswire | Image: Jazz